BriaCell Therapeutics Corp. SEC filings BCTXL
BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Feb 12, 2026 | Feb 12, 2026 |
| DEFA14A | Additional proxy material | Jan 3, 2025 | — |
| DEF 14A | Proxy statement | Dec 17, 2024 | Dec 17, 2024 |
| DEF 14A | Proxy statement | Jan 9, 2024 | Jan 9, 2024 |
| DEF 14A | Proxy statement | Jul 26, 2023 | Jul 26, 2023 |
| PRE 14A | Preliminary proxy statement | Jun 30, 2023 | Jun 30, 2023 |
| DEF 14A | Proxy statement | Jan 17, 2023 | Jan 17, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 5, 2023 | Jan 5, 2023 |
Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.